Blue Owl Capital Inc. (OWL) Stock Price & Analysis
Blue Owl Capital Inc. (OWL) closed at USD 9.71 on Thursday, October 22, 2026, up 5.89% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 9.17; the Oct 22, 2026 session ranged USD 8.96–9.72 on volume of 32,634,736 shares. Market capitalization is $15.22B, with a 52-week range of USD 7.95–17.3 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:25 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OWL.md
Key facts (OWL)
- Last four reported quarters (through Jun 30, 2026): revenue $2.99B, net income $80.9M (2.7% margin), free cash flow $1.32B (SEC filings).
- Valuation: P/E 188.1x (avg 125.0x at the last 3 fiscal year-ends), net debt $3.64B.
- Earnings quality: non-operating income -$116M vs operating income null over the last four quarters; P/E excluding non-operating income ≈83.9x (estimate: non-operating income taxed at the company's 13.2% effective rate).
- Analysts: Buy (mean 2.22 on a 1–5 scale) (18 analysts), mean target USD 12.44 (range 9–20).
- Total return with dividends: 1Y -35.7% vs S&P 500 +14.9%; 5Y -28.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 0.23, revenue estimate $703M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OWL)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $824M | $1.37B | $1.73B | $2.30B | $2.87B | $2.99B |
| Net income | -$376M | -$9.3M | $54.3M | $110M | $78.8M | $80.9M |
| EPS (diluted) | — | -$0.02 | $0.10 | $0.20 | $0.10 | — |
| Free cash flow | $276M | $663M | $881M | $935M | $1.20B | $1.32B |
| Net margin | -45.7% | -0.7% | 3.1% | 4.8% | 2.7% | 2.7% |
| Revenue growth | +229.8% | +66.3% | +26.4% | +32.6% | +25.0% | — |
| Cash + short-term investments | $42.6M | $68.1M | $104M | $152M | $195M | — |
| Total debt | $1.17B | $1.62B | $1.68B | $2.59B | $3.32B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (OWL)
P/E 188.1x · P/E ex non-operating (est.) ≈83.9x · P/S 5.1x · EV/Sales 6.3x · P/FCF 11.5x · P/B 7.6x · FCF yield 8.70% · Earnings yield 0.53% · Dividend yield (paid, TTM) 3.96% · Buyback yield (TTM) 0.51% · Net debt $3.64B · EV $18.9B
P/E at fiscal year-ends: Dec 2025 125.4x, Dec 2024 118.5x, Dec 2023 131.1x.
Analysts (OWL)
Consensus Buy (mean 2.22 on a 1–5 scale), 18 analysts; mean target USD 12.44 (low 9, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Piper Sandler | Target lowered | Overweight | $13 → $12 |
| 2026-10-12 | TD Cowen | Target raised | Buy | $15 → $16 |
| 2026-10-02 | Wells Fargo | Initiated | Equal-Weight | $10 |
| 2026-08-27 | Oppenheimer | Target raised | Outperform | $15 → $17 |
| 2026-08-03 | Goldman Sachs | Target raised | Neutral | $9.5 → $10.5 |
| 2026-08-03 | BMO Capital | Target raised | Outperform | $11 → $12 |
| 2026-07-31 | Barclays | Target raised | Equal-Weight | $9 → $10 |
| 2026-07-17 | Oppenheimer | Target lowered | Outperform | $16 → $15 |
| 2026-07-13 | BMO Capital | Target lowered | Outperform | $12 → $11 |
| 2026-07-09 | Citizens | Target lowered | Market Outperform | $21 → $17 |
| 2026-07-09 | Barclays | Target lowered | Equal-Weight | $10 → $9 |
Total return (dividends reinvested) (OWL)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -35.7% | -28.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -35.8% | -6.5% |
| Volatility (annualized) | 45.5% | 43.8% |
| Max drawdown | -49.6% (Dec 2025→Apr 2026) | -67.1% (Jan 2025→Apr 2026) |
Companies that name OWL in their SEC reports
| Relationship to OWL | Company | Filing | Sentence |
|---|---|---|---|
| partner | Finance of America Companies Inc. (FOA) | 10-K Mar 13, 2026 | “Further, in December 2025, we announced a strategic partnership with funds managed by Blue Owl Capital, Inc. ("Blue Owl"), which includes a joint innovation and product-development initiative focused on the continuous rollout of new, differentiated financial products tailored for people looking to maximize freedom, security, and opportunity throughout their” |
| partner | TG THERAPEUTICS, INC. (TGTX) | 10-K Feb 27, 2026 | “On August 2, 2024 (the New Closing Date), we entered into a term loan facility of $250 million (the Initial Term Loan) with Blue Owl Capital Corporation, as administrative agent (the Administrative Agent), HealthCare Royalty and Blue Owl Capital under the Financing Agreement (as defined below) to repay all outstanding principal and accrued interest and fees under our prior loan agreement with Hercules.” |
| partner | BridgeBio Pharma, Inc. (BBIO) | 10-K Feb 24, 2026 | “On January 17, 2024, we entered into a Financing Agreement with each of the guarantors, which was amended on February 12, 2024 (the "Financing Agreement") and June 20, 2024 (the Financing Agreement, as amended by the Second Amendment, the "Amended Financing Agreement"), with the lenders party thereto (the "Lenders") and Blue Owl Capital Corporation, as administrative agent for the Lenders (the "Administrative Agen…” |
| partner | Blue Owl Technology Finance Corp. (OTF) | 10-K Feb 18, 2026 | “Blue Owl Leasing, a Delaware limited liability company, is a joint venture among the Company, Blue Owl Capital Corporation, Blue Owl Capital Corporation II, Blue Owl Credit Income Corp., Blue Owl Technology Income Corp., Alternative Credit Fund and California State Teachers Retirement System (each, a "Blue Owl Leasing Member" and collectively, the "Blue Owl Leasing Members").” |
OWL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.23 | $0.23 | -0.2% | $702.9M | 16 |
| Next quarter (ends Dec 2026) | $0.25 | $0.24 | +1.7% | $747.8M | 15 |
| Current fiscal year (ends Dec 2026) | $0.88 | $0.87 | +1.1% | $2.85B | 17 |
| Next fiscal year (ends Dec 2027) | $0.98 | $0.98 | -0.1% | $3.14B | 17 |
OWL options: expected move
Options price a move of about ±7.8% (±$0.75) by Oct 30, 2026, which includes earnings on Oct 29, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 66.5% | ±7.8% |
| Nov 6, 2026 | 14 | 58.2% | ±9.9% |
| Nov 13, 2026 | 21 | 53.3% | ±11.2% |
| Nov 20, 2026 | 28 | 52.9% | ±12.2% |
| Nov 27, 2026 | 35 | 48.2% | ±12.2% |
| Dec 4, 2026 | 42 | 56.9% | ±15.6% |
| Dec 18, 2026 | 56 | 47.2% | ±15.8% |
| Jan 15, 2027 | 84 | 45.8% | ±18.2% |
30-day implied volatility 50.1% vs 35.4% realized over the last 30 trading days. Put/call ratio (volume) 0.17. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:25 UTC)
| Price | USD 9.71 |
|---|---|
| Change | ▲ 5.89% (up) |
| Previous Close | USD 9.17 |
| Open | USD 8.99 |
| Day Range | USD 8.96 – 9.72 |
| 52-Week Range | USD 7.95 – 17.3 |
| Volume | 32,634,736 shares |
| Market Cap | $15.22B |
| Exchange | NYQ |
Technical Analysis (OWL)
Nexqual's technical model rates OWL "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:25 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 49.19 (neutral) |
| vs SMA50 | Below (USD 10.34) |
| MACD | -0.24 (negative) |
Analyst Ratings (OWL)
Wall Street analysts rate OWL "Buy" based on 18 analysts, with a mean price target of USD 12.44 (range USD 9–20), per Nexqual as of October 23, 2026 at 09:25 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 12.44 |
| High Target | USD 20 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 11 / 7 / 0 |
Earnings (OWL)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 0.23 |
| Revenue Estimate | $702.88M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.22 vs est 0.22 ▲ beat |
| 2026-03-31 | USD 0.19 vs est 0.18 ▲ beat |
| 2025-12-31 | USD 0.24 vs est 0.22 ▲ beat |
| 2025-09-30 | USD 0.22 vs est 0.22 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financials & Fundamentals (OWL)
| Total Revenue | $2.99B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +7.10% |
| Gross Margin | +58.49% |
| Operating Margin | +28.94% |
| Profit Margin | +2.71% |
| ROE | +5.65% |
| Debt / Equity | 0.77 |
| Current Ratio | 1.98 |
| Total Cash | $169.06M |
| Total Debt | $4.34B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $1.32B (44.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financial Health Score (OWL)
Nexqual rates Blue Owl Capital Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:25 UTC.
| Growth | Strong — Revenue +22% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 58%, operating 29% (last 12 months) |
| Balance Sheet | Mixed — $169M cash and investments vs $3.81B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $1.32B (last 4 quarters to Jun 2026, SEC), 44% margin |
| Efficiency | Mixed — ROE 6%, ROA 4.5% |
Ownership (OWL)
| Insider Ownership | +0.12% |
|---|---|
| Institutional Ownership | +96.45% |
| Shares Outstanding | 683.91M |
| Float | 648.53M |
| Short % of Float | +17.66% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Leadership (OWL)
Blue Owl Capital Inc. is led by Douglas Irving Ostrover, Co-Founder, Chairman & Co-CEO, per Nexqual as of October 23, 2026 at 09:25 UTC.
| Co-Founder, Chairman & Co-CEO | Douglas Irving Ostrover |
|---|---|
| Co-Founder, Co-CEO & Director | Marc S. Lipschultz |
| Co-Founder, Co-President & Director | Michael Douglass Rees |
| Head of Credit, Co-Founder, Co-President, Senior MD & Director | Craig William Packer |
| Co-President & Director | Marc Zahr |
Major Backers & Investors (OWL)
Notable institutional backers of Blue Owl Capital Inc. include Capital Group, FMR, LLC, ICONIQ Capital, LLC, according to Nexqual as of October 23, 2026 at 09:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 14.2% |
| FMR, LLC | 9.9% |
| ICONIQ Capital, LLC | 5.02% |
| AMERICAN BALANCED FUND | 4.42% |
| Fidelity | 4.09% |
| Bank of America Corporation | 3.3% |
| Growth Fund of America | 3.09% |
| Lind Value II ApS | 2.44% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.27% |
| BlackRock | 4.62% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHYS | "Sprott Physical Gold Trust" | USD 30.39 | ▼ 2.72% |
| EQH | Equitable Holdings, Inc. | USD 55.04 | ▲ 1.23% |
| CG | The Carlyle Group Inc. | USD 39.2 | ▲ 5.18% |
| ARCC | Ares Capital Corporation | USD 18.79 | ▲ 2.12% |
| CRBG | Corebridge Financial Inc. | USD 35.59 | ▲ 0.82% |
| SEIC | SEI Investments Company | USD 104.5 | ▼ 3.62% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:25 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt